Acute Radiation Syndrome
Conditions
Brief summary
This trial is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic of KMRC011 injection in healthy adult volunteers.
Interventions
DRUGKMRC011 5μg or Placebo
Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
DRUGKMRC011 10μg or Placebo
Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
DRUGKMRC011 15μg or Placebo
Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
DRUGKMRC011 20μg or Placebo
Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
DRUGKMRC011 25μg or Placebo
Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
Sponsors
Intron Biotechnology, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* A male whose age is between 19 and 55 years of age * A person whose body mass index is between 18.5 and 27 kg/m2 at screening * A person who has the ability and willingness to participate in the clinical trial * A person who voluntarily agrees with the clinical trial after hearing and fully understanding the detailed explanation of this clinical trial
Exclusion criteria
* A person who has a clinically significant disease or history of liver, kidney, neuropsychiatry, immune system, respiratory system, endocrine system, hematology\*oncology system, cardiovascular system, etc.(In the case of liver disease items, it includes subjects who have hepatitis virus) * A person who has clinical history of hypersensitivity reactions to the major components or constituents of investigational product or other clinically significant hypersensitivity reactions to drugs or foods, or those with allergic diseases requiring treatment * A person with infectious disease or severe trauma within 21 days of the randomization date * A person whose serum AST, ALT or γ-GT levels exceed 1.5 times the upper limit of the reference range at screening * A person whose QTcF on the electrocardiogram exceeds 430 msec or who has a clinically significant abnormal rhythm at screening * A person with a glomerular filtration rate less than 60 mL/min/1.73 m2 calculated from serum creatinine at screening * A person with a systolic blood pressure less than 100 mmHg, greater than 150 mmHg, diastolic blood pressure less than 60 mmHg, or greater than 100 mmHg at screening * A person with thrombocytopenia or coagulopathy which should not be given intramuscular injection * A person whose weekly average drinking amount exceeds 140g of alcohol per week * A person whose daily average smoking amount exceeds 10 per day * A person who have received a drug that can significantly affect the absorption, distribution, metabolism or excretion of the investigational product within 14 days of the injection * A person who has the history of substance abuse or positive urine screening test * A person who have received a investigational product or a bioequivalence study drug within at least 90 days prior to the randomization * A person who donated whole blood within 60 days before the randomization, or donated components of blood within 30 days * A person who dose not have a medically approved contraceptive during the trial and has a plan to provide sperm * A person who has clinically significant abnormalities from clinical laboratory test * A person who is deemed ineligible for clinical trials by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of IL-6 | Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose |
| Maximum effect over the time span specified (Emax) of IL-6 | Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose |
| Area under the effect versus time curve, from time 0 to the last measurable concentration (AUEC0-t) of G-CSF | Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose |
| Number of subjects with treatment-emergent adverse event or adverse drug reaction | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in hematology test result after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in blood chemistry test result after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in urinalysis test result after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in blood coagulation test result after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in ECG (Electrocardiogram) after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant changes in vital sign after injection | Up to 7±1 days after injection |
| Number of subjects with clinically significant physical abnormality after injection | Up to 7±1 days after injection |
| Maximum serum concentration (Cmax) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Time of the maximum serum concentration (Tmax) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Area under the serum concentration versus time curve, from time 0 to the last measurable concentration (AUC0-t) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Area under the serum concentration versus time curve from time 0 to infinity (AUCinf) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Percentage of AUCinf due to extrapolation from time of last measurable concentration to infinity (AUCextra) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Apparent clearance (CL/F) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Apparent volume of distribution (Vd/F) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Terminal half-life (t1/2) of KMRC011 | Pre-dose(0 hours) and 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 hours post-dose |
| Maximum effect over the time span specified (Emax) of G-CSF | Pre-dose(0 hours) and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48 hours post-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of KMRC011 | Until the study completion, approximately up to 35 weeks | A dose that is one level lower than the dose which Dose Limiting Toxicity (DLT) incidence is 33% or more is determined as a Maximum Tolerated Dose (MTD). If the Dose Limiting Toxicity (DLT) incidence is lower than 33% at all doses level, we conclude Maximum Tolerated Dose (MTD) cannot be determined. |
Other
| Measure | Time frame |
|---|---|
| Number of subjects who expressed Anti-Drug (KMRC011) Antibody (ADA) | Up to 28±2 days after injection |
Countries
South Korea
Outcome results
None listed